AU2016233772A1 - Method of discovery of effective components in herbals based on evidences by reversed-directed analysis - Google Patents
Method of discovery of effective components in herbals based on evidences by reversed-directed analysis Download PDFInfo
- Publication number
- AU2016233772A1 AU2016233772A1 AU2016233772A AU2016233772A AU2016233772A1 AU 2016233772 A1 AU2016233772 A1 AU 2016233772A1 AU 2016233772 A AU2016233772 A AU 2016233772A AU 2016233772 A AU2016233772 A AU 2016233772A AU 2016233772 A1 AU2016233772 A1 AU 2016233772A1
- Authority
- AU
- Australia
- Prior art keywords
- patients
- compounds
- herbals
- effective
- website
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000004458 analytical method Methods 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 54
- 238000012360 testing method Methods 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 9
- 235000008216 herbs Nutrition 0.000 claims description 7
- 238000007619 statistical method Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 4
- 238000007477 logistic regression Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000004590 computer program Methods 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 238000000540 analysis of variance Methods 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000008092 positive effect Effects 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 238000012827 research and development Methods 0.000 abstract description 2
- 238000007796 conventional method Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000004044 response Effects 0.000 description 16
- 239000000090 biomarker Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4854—Diagnosis based on concepts of alternative medicine, e.g. homeopathy or non-orthodox
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/90—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Primary Health Care (AREA)
- Data Mining & Analysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Artificial Intelligence (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Alternative & Traditional Medicine (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biotechnology (AREA)
- Evolutionary Biology (AREA)
- Bioethics (AREA)
- Theoretical Computer Science (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562177349P | 2015-03-13 | 2015-03-13 | |
| US62/177,349 | 2015-03-13 | ||
| US14/866,924 | 2015-09-26 | ||
| US14/866,924 US20160085941A1 (en) | 2015-03-13 | 2015-09-26 | Method of Discovery of Effective Components in Herbals Based on Evidences by Reversed-directed Analysis |
| PCT/US2016/020789 WO2016148936A1 (en) | 2015-03-13 | 2016-03-03 | Method of discovery of effective components in herbals based on evidences by reversed-directed analysis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016233772A1 true AU2016233772A1 (en) | 2017-08-17 |
Family
ID=55525998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016233772A Abandoned AU2016233772A1 (en) | 2015-03-13 | 2016-03-03 | Method of discovery of effective components in herbals based on evidences by reversed-directed analysis |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160085941A1 (https=) |
| EP (1) | EP3268926A4 (https=) |
| JP (1) | JP2018508084A (https=) |
| CN (1) | CN108351328A (https=) |
| AU (1) | AU2016233772A1 (https=) |
| WO (1) | WO2016148936A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102376173B1 (ko) * | 2019-12-27 | 2022-03-21 | 한국식품연구원 | 식치 정보의 관리 방법 및 장치 |
| CN118671248B (zh) * | 2024-08-23 | 2024-12-03 | 山东齐都药业有限公司 | 逆向分析聚原酸酯原料的方法及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6113907A (en) * | 1997-04-15 | 2000-09-05 | University Of Southern California | Pharmaceutical grade St. John's Wort |
| US6156291A (en) * | 1997-08-28 | 2000-12-05 | Cv Technologies Inc. | Chemical and pharmacological standardization of herbal extracts |
| JPH11193240A (ja) * | 1997-12-26 | 1999-07-21 | Meiji Milk Prod Co Ltd | 脂質代謝改善組成物 |
| JP2001357131A (ja) * | 2000-06-12 | 2001-12-26 | Kanai Tokichi Shoten:Kk | 通信ネットワークを介して漢方薬の処方を提供する方法 |
| US20050283385A1 (en) * | 2004-06-21 | 2005-12-22 | The Permanente Medical Group, Inc. | Individualized healthcare management system |
| JP2008097154A (ja) * | 2006-10-06 | 2008-04-24 | Fujitsu Ltd | 相互作用分析プログラムおよび相互作用分析装置 |
| CA2672408C (en) * | 2007-03-30 | 2019-07-23 | 9898 Limited | Pharmacokinetic and pharmacodynamic modelling and methods for the development of phytocompositions or other multi-component compositions |
| JP2013012025A (ja) * | 2011-06-29 | 2013-01-17 | Fujifilm Corp | 診療支援システムおよび方法、並びに、プログラム |
| CN103065066B (zh) * | 2013-01-22 | 2015-10-28 | 四川大学 | 基于药物组合网络的药物联合作用预测方法 |
| US20150339442A1 (en) * | 2013-12-04 | 2015-11-26 | Mark Oleynik | Computational medical treatment plan method and system with mass medical analysis |
-
2015
- 2015-09-26 US US14/866,924 patent/US20160085941A1/en not_active Abandoned
-
2016
- 2016-03-03 AU AU2016233772A patent/AU2016233772A1/en not_active Abandoned
- 2016-03-03 JP JP2017548209A patent/JP2018508084A/ja active Pending
- 2016-03-03 EP EP16765419.3A patent/EP3268926A4/en not_active Withdrawn
- 2016-03-03 CN CN201680003852.3A patent/CN108351328A/zh active Pending
- 2016-03-03 WO PCT/US2016/020789 patent/WO2016148936A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016148936A1 (en) | 2016-09-22 |
| JP2018508084A (ja) | 2018-03-22 |
| US20160085941A1 (en) | 2016-03-24 |
| WO2016148936A8 (en) | 2017-03-30 |
| EP3268926A1 (en) | 2018-01-17 |
| CN108351328A (zh) | 2018-07-31 |
| EP3268926A4 (en) | 2018-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Effect of exercise on quality of life in Parkinson’s disease: a systematic review and meta‐analysis | |
| Sun et al. | The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review | |
| Picardi et al. | Delusional themes across affective and non-affective psychoses | |
| Landgrebe et al. | The Tinnitus Research Initiative (TRI) database: a new approach for delineation of tinnitus subtypes and generation of predictors for treatment outcome | |
| Siemens et al. | Pharmacological interventions for pruritus in adult palliative care patients | |
| Gross et al. | Brazilian version of the Problem Areas in Diabetes Scale (B-PAID): validation and identification of individuals at high risk for emotional distress | |
| Xander et al. | Pharmacological interventions for pruritus in adult palliative care patients | |
| Stahler et al. | The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US | |
| Gagnier et al. | An empirical study using permutation-based resampling in meta-regression | |
| Linde et al. | Should systematic reviews include non-randomized and uncontrolled studies? The case of acupuncture for chronic headache | |
| Jacobsen et al. | Comparing objective cognitive impairments in patients with peripheral neuropathic pain or fibromyalgia | |
| Abdulrahman | Investigating the role of gut microbiota dysbiosis in the pathogenesis and advancement of Alzheimer's disease: a comprehensive multi-omics approach | |
| Kim et al. | Association of chemotherapy and subjective cognitive impairment in breast cancer patients: Meta-analysis of longitudinal prospective cohort studies | |
| Pindus et al. | Effects of reducing sedentary behaviour duration by increasing physical activity, on cognitive function, brain function and structure across the lifespan: a systematic review protocol | |
| Spreen et al. | Optogenetic behavioral studies in depression research: A systematic review | |
| Omondi et al. | Improving rigor and reproducibility in western blot experiments with the blotRig analysis | |
| Wang et al. | Traditional Chinese medicine in the management of anxiety disorders: a narrative review of theoretical foundations, clinical applications, and modern integrative approaches | |
| US20160085941A1 (en) | Method of Discovery of Effective Components in Herbals Based on Evidences by Reversed-directed Analysis | |
| Meini et al. | Relationship between plasma concentrations of the l-enantiomer of methadone and response to methadone maintenance treatment | |
| Machado et al. | Cognitive impairment and quality of life of patients subjected to hematopoietic stem cell transplantation | |
| Parsonson | Guest Editorial: The case for practice-based evidence to support evidence-based practice | |
| Valsecchi et al. | Breast-cancer specific comprehensive archive of patient-reported outcome measures (PROMs) for clinical research and clinical practice in oncology: results from the PRO4All project | |
| Goto et al. | Prevalence and coexistence of locomotive syndrome with reduced mobility and metabolic syndrome: a cross-sectional study of 35,059 Japanese adults | |
| Ochonu | Application of Meta-Analysis for Assessing Correlational Data in Diabetic Patients | |
| Zhang | Method of discovery of effective components in herbals based on evidence by reversed-directed analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |